Table 4. Effect of Therapeutic Strategies on the Blood-Brain Barrier in AD Models.
Table 4 lists studies indicated in Figure 6 that show the effects of therapeutics strategies in transgenic AD mice and rats. References: (Batarseh, et al., 2017; Batarseh & Kaddoumi, 2018; Beckmann, Gerard, Abramowski, Cannet, & Staufenbiel, 2011; Bien-Ly, et al., 2015; Blockx, et al., 2016; Burbach, et al., 2007; Burgess, Dubey, et al., 2014; Burgess, Nhan, Moffatt, Klibanov, & Hynynen, 2014; Chauhan & Sandoval, 2007; Chauhan, Siegel, & Lichtor, 2004; J. J. Choi, et al., 2008; Cortes-Canteli, et al., 2019; Dubey, et al., 2020; Elfakhri, et al., 2019; Fan, DeFilippis, & Van Nostrand, 2007; Faraco, et al., 2016; Fitz, et al., 2014; Hattori, et al., 2016; Herring, et al., 2010; Hur, et al., 2018; Jordao, et al., 2010; Jordao, et al., 2013; Kook, et al., 2014; Lazic, et al., 2019; W. J. Lee, et al., 2020; Leinenga & Gotz, 2018; Leinenga, Koh, & Gotz, 2019; M. Liu, et al., 2018; X. Liu, et al., 2019a, 2019b; Lynch, et al., 2021; Marinescu, et al., 2017; Michael, et al., 2019; Mueggler, et al., 2003; Nyul-Toth, et al., 2020; Ongali, et al., 2014; Pandit & Mukhopadhyay, 2004; Y. H. Park, et al., 2020; Passos, Kilday, Gillen, Cribbs, & Vasilevko, 2016; Poduslo, Curran, Wengenack, Malester, & Duff, 2001; Poon, Pellow, & Hynynen, 2021; Reuter, Venus, Grudzenski, et al., 2016; Robison, et al., 2020; Royea, Martinot, & Hamel, 2020; Saito, Buciak, Yang, & Pardridge, 1995; Schultheiss, et al., 2006; Shabir, et al., 2020; Sharp, et al., 2019; J. Song, Choi, Whitcomb, & Kim, 2017; St-Amour, et al., 2013; Takeda, et al., 2009; Thakker, et al., 2009; Uekawa, et al., 2016; Van Skike, et al., 2018; Vasilevko, Xu, Previti, Van Nostrand, & Cribbs, 2007; Weber-Adrian, et al., 2019; Xhima, et al., 2020; Xie, et al., 2020; Xiong, et al., 2021; M. Xu, et al., 2020; J. Yan, et al., 2015; P. Yan, et al., 2015).
| # In Fig. 6 | Therapeutic Strategy | Model | Reference |
|---|---|---|---|
| 1 | Angiotensin Receptor Blockers | Tg2576 Mice | Nyül-Töth et al. 2020; Passos et al. 2016; Faraco et al. 2016 |
| 2 | Angiotensin Receptor Blockers | APP23 Mice | Takeda et al. 2009 |
| 3 | Angiotensin Receptor Blockers | hAPP (J20) Mice | Ongali et al. 2014; Royea et al. 2020 |
| 4 | Angiotensin Receptor Blockers | TgSwDI Mice | Faraco et al. 2016 |
| 5 | Angiotensin Receptor Blockers | 5xFAD Mice | Uekawa et al. 2016 |
| 6 | Antibiotics | Tg2576 Mice hAPP (J20) Mice | Yan et al. 2015 |
| 7 | Antibiotics | Tg2576 Mice hAPP (J20) Mice | Van Skike et al. 2018 |
| 8 | Antibiotics | TgSwDI Mice | Fan et al. 2007 |
| 9 | Antibiotics | 5xFAD Mice | Yan et al. 2015 |
| 10 | Anticoagulants | Tg2576 Mice | Micheal et al. 2019 |
| 11 | Anticoagulants | APP23 Mice | Marinescu et al. 2017 |
| 12 | Anticoagulants | TgCRND8 Mice | Cortes-Canteli et al. 2019 |
| 13 | Anticoagulants | 5xFAD Mice | Lazic et al. 2019 |
| 14 | Antioxidants | Tg2576 Mice | Park et al. 2020; Han et al. 2015 |
| 15 | Antioxidants | APP23 Mice | Liu et al. 2019a; Liu et al. 2019b |
| 16 | Antioxidants | TgSwDI Mice | Saito et al. 2017 |
| 17 | Antioxidants | APP/PS1 Mice | Xu et al 2020 |
| 18 | Antioxidants | 5xFAD Mice | Elfakhri et al 2019; Batarseh & Kaddoumi, 2018; Song et al. 2017; Batarseh et al. 2017; Kook et al. 2014 |
| 19 | Cranial / Cognitive Stimulations | APP23 Mice | Mueggler et al. 2003 |
| 20 | Cranial / Cognitive Stimulations | hAPP (J20) Mice | Shabir et al. 2020; Sharp et al. 2019 |
| 21 | Cranial / Cognitive Stimulations | TgCRND8 Mice | Herring et al. 2010 |
| 22 | Cranial / Cognitive Stimulations | TgSwDI Mice | Robison et al. 2020 |
| 23 | Immunosuppressants | hAPP (J20) Mice | Van Skike et al. 2018 |
| 24 | Passive Immunotherapies | PDAPP Mice | Blockx et al. 2016 |
| 25 | Passive Immunotherapies | Tg2576 Mice | Thakker et al. 2009 |
| 26 | Passive Immunotherapies | APP23 Mice | Burbach et al. 2007; Fitz et al. 2014; Beckmann et al. 2011 |
| 27 | Passive Immunotherapies | TgCRND8 Mice | Dubey et al. 2020; Jordäo et al. 2010; Chauhan, 2007; Chauhan et al. 2004 |
| 28 | Passive Immunotherapies | TgSwDI Mice | Vasilevko et al. 2007 |
| 29 | Passive Immunotherapies | 3xTg-AD | St-Amour et al. 2013 |
| 30 | Passive Immunotherapies | Tau P301L Mice | Bien-Ly et al. 2015 |
| 31 | Passive Immunotherapies | APP/PS1 Mice | Podulso et al. 2001 |
| 32 | Passive Immunotherapies | 5xFAD Mice | Xiong et al. 2021 |
| 33 | Scanning / Focused Ultrasound | APP23 Mice | Leinenga et al. 2019; Leinenga & Götz, 2018 Poon et al. 2021; Lynch et al. 2021; Dubey et al. 2020 |
| 34 | Scanning / Focused Ultrasound | TgCRND8 Mice | Liu et al. 2018; Burgess et al. 2014a; Burgess et al. 2014b; Jordäo et al. 2013; Jordäo et al. 2010; Xhima et al. 2020; Weber-Adrian et al. 2019; |
| 35 | Scanning / Focused Ultrasound | Tau P301L Mice | Pandit et al. 2019 |
| 36 | Scanning / Focused Ultrasound | APP/PS1 Mice | Choi et al 2008 |
| 37 | Scanning / Focused Ultrasound | 5xFAD Mice | Lee et al. 2020 |
| 38 | Short-Chain Fatty Acids | Tg2576 Mice | Hur et al. 2018 |
| 39 | Short-Chain Fatty Acids | APP23 Mice | Reuter et al 2016 |
| 40 | Short-Chain Fatty Acids | APP/PS1 Mice | Xie et al. 2020 |
| 41 | Statins & NSAIDs | Tg2576 Mice | Garcia-Alloza et al. 2009 |
| 42 | Statins & NSAIDs | APP23 Mice | Reuter et al. 2016; Schultheiss et al. 2006 |
| 43 | Statins & NSAIDs | TgSwDI Mice | Hattori et al. 2016 |